Ocular Therapeutix Investor Relations Material
Latest events
Q4 2024
Ocular Therapeutix
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Ocular Therapeutix Inc
Access all reports
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company offers Rhopressa (generic name: tetrahydroprochlorothiazide/timolol maleate) for the treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
OCUL
Country
🇺🇸 United States